- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Cipla EU to acquire additional 19.16 percent stake in Cipla Maroc
New Delhi: Cipla (EU) Limited, wholly owned subsidiary of the Company in UK, has agreed to acquire an additional 19.16% stake in Cipla Maroc SA, joint venture and subsidiary of Cipla EU in Morocco.
The said acquisition is for a total consideration of MAD (Moroccan Dirham) 102.90 million (Rs79.51 crore approx.).
Cipla Maroc SA ("JV Co.") was incorporated in 2015, in Morocco, as a joint venture between Cipla EU Limited (60%), The Pharmaceutical Institute ("PHI") (24.20%) and Societe Marocaine De Cooperation Pharmaceutique ("Cooper Pharma") (15.80%) for the purpose of manufacturing, marketing and distribution of pharmaceutical products in Morocco.
Pursuant to the change in control of PHI and as per the terms of the existing Joint Venture Agreement, PHI is disposing off its shareholding in the JV Co. Accordingly, the entire stake held by PHI in the JV Co. will be acquired by Cipla EU and Cooper Pharma in proportion to their existing shareholding ("Proposed Transaction").
"The JV Co. has a highly strategic product portfolio and is one of the rapidly growing businesses in the emerging market region for Cipla. Further investment in the JV Co. will provide an exit to PHI and will help Cipla consolidate its holding in the JV Co. and deepen its presence in a strategically important Moroccan market," Cipla stated.
Read also: Cipla names Dr Mandar Purushottam Vaidya as Additional, Independent Director
The JV Co. has a manufacturing facility set-up in Morocco and is primarily focussed on respiratory and CNS products.
Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751